NeurologyLive® Friday 5 — February 24, 2023

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Top News for World Encephalitis Day

For World Encephalitis Day— February 22, 2023—the team has culminated some of the biggest pieces of news and insightful exchanges with physicians to offer updates on new developments in literature and expert opinions about autoimmune encephalitis to spread awareness on the prevention and treatment of the condition.

2: Peer Exchange: Expert Perspectives on Recent Advances in Alzheimer’s Disease

In this Peer Exchange series, a panel of experts in dementia discusses the latest progress in the treatment of Alzheimer disease, and the various therapies that have progressed through the pipeline. The NeurologyLive® series panel features Marwan Sabbagh, MD; Alireza Atri, MD, PhD; Sharon Cohen, MD, FRCPC; and Eric McDade, DO.

3: NeuroVoices: Shazam Hussain, MD, FRCP, FAHA, on Weighing Direct to Angio Approaches for Mobile Stroke Units

In the latest edition of our in-depth Q&A series, the director of Cleveland Clinic’s Cerebrovascular Center provided clinical perspective on the treatment decisions mobile stroke units face, and whether directly transferring patients to angiography suite is necessary. Hussain also talked about identifying subgroups of patients who may be more suitable for direct-to-angio approaches, and the clinical areas of stroke you’d like to see grow in the coming years.

4: Clinician Perspectives on Black History Month

As part of our efforts to recognize contributions both past and present, NeurologyLive® spoke with several Black leaders in the neurology community to learn more about their experience in health care, what or who has inspired them, and how they are helping their communities overcome disparities.

5: Episode 83: The ARISE Study and Using DMTs in RIS

Episode 83, "The ARISE Study and Using DMTs in RIS," features an exclusive interview with Darin Okuda, MD, FAAN, FANA, director of Neuroinnovation and Multiple Sclerosis & Neuroimmunology Imaging Program at UT Southwestern Medical Center. He spoke about the phase 2 ARISE study assessing dimethyl fumarate (Tecfidera; Biogen) in patients with radiologically isolated syndrome, the significance of the findings, next steps in validating this therapy, and more. [LISTEN TIME: 16 minutes]